BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36951195)

  • 21. A clinicopathological experience in acute myeloid leukemia: Effects of clinical data and status of FLT3, CEBPA and NPM1 on prognosis.
    Yener E; Ozcan K; Öngören Ş; Salihoğlu A; Demiröz AS; Akı H
    Indian J Pathol Microbiol; 2022; 65(3):642-648. PubMed ID: 35900493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic biomarkers identify a subgroup of high-risk patients within low-risk
    Carbonell D; Suárez-González J; Chicano M; Andrés-Zayas C; Díez-Díez M; Rodríguez-Macías G; Muñiz P; Kwon M; Anguita J; Díez-Martín JL; Buño I; Martínez-Laperche C
    Leuk Lymphoma; 2021 May; 62(5):1178-1186. PubMed ID: 33372822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of genomics in the clinical management of patients with cytogenetically normal acute myeloid leukemia.
    Falini B; Martelli MP
    Best Pract Res Clin Haematol; 2015; 28(2-3):90-7. PubMed ID: 26590764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemotherapeutic Resistance in Egyptian Acute Myeloid Leukemia Patients.
    Kassem NM; Medhat N; Kassem HA; El-Desouky MA
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2421-2427. PubMed ID: 31450916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Association of Next Generation Sequencing Based Genotypic Profiling with MICM Characteristics in NPM1 Mutated Acute Myeloid Leukemia].
    Wang B; Ling Y; Dai L; Gu WY; Zhang XW; Xing SS; Li HQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):56-60. PubMed ID: 35123604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.
    Rubio P; Campos B; Digiorge JA; Gallego MS; Medina A; Rossi JG; Felice MS; Alonso CN
    Int J Hematol; 2016 Nov; 104(5):582-590. PubMed ID: 27436336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis].
    Li L; Lyu XD; Mi RH; Ding J; Chen L; Wang Q; Yin QS; Hu JY; Fan RH; Wei XD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):601-6. PubMed ID: 23815906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute myeloid leukemia: 2013 update on risk-stratification and management.
    Estey EH
    Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study.
    Mrózek K; Kohlschmidt J; Blachly JS; Nicolet D; Carroll AJ; Archer KJ; Mims AS; Larkin KT; Orwick S; Oakes CC; Kolitz JE; Powell BL; Blum WG; Marcucci G; Baer MR; Uy GL; Stock W; Byrd JC; Eisfeld AK
    Leukemia; 2023 Apr; 37(4):788-798. PubMed ID: 36823396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.
    El Gammal MM; Ebid GT; Madney YM; Abo-Elazm OM; Kelany AK; Torra OS; Radich JP
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e281-e290. PubMed ID: 30926392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
    Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
    N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
    Kim M; Williams S
    Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
    Paschka P; Marcucci G; Ruppert AS; Whitman SP; Mrózek K; Maharry K; Langer C; Baldus CD; Zhao W; Powell BL; Baer MR; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD
    J Clin Oncol; 2008 Oct; 26(28):4595-602. PubMed ID: 18559874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular genetic tests for FLT3, NPM1, and CEBPA in acute myeloid leukemia.
    Zhang Q; Bai S; Vance GH
    Methods Mol Biol; 2013; 999():105-21. PubMed ID: 23666693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics.
    Gregory TK; Wald D; Chen Y; Vermaat JM; Xiong Y; Tse W
    J Hematol Oncol; 2009 Jun; 2():23. PubMed ID: 19490647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.
    Gou H; Zhou J; Ye Y; Hu X; Shang M; Zhang J; Zhao Z; Peng W; Zhou Y; Zhou Y; Song X; Lu X; Ying B
    Tumour Biol; 2016 Jun; 37(6):7357-70. PubMed ID: 26676635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FLT3-TKD Mutations Associated With NPM1 Mutations Define a Favorable-risk Group in Patients With Acute Myeloid Leukemia.
    Perry M; Bertoli S; Rocher C; Hayette S; Ducastelle S; Barraco F; Labussière-Wallet H; Salles G; Recher C; Thomas X; Paubelle E
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e545-e550. PubMed ID: 30082225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A precision medicine classification for treatment of acute myeloid leukemia in older patients.
    Mims AS; Kohlschmidt J; Borate U; Blachly JS; Orwick S; Eisfeld AK; Papaioannou D; Nicolet D; Mrόzek K; Stein E; Bhatnagar B; Stone RM; Kolitz JE; Wang ES; Powell BL; Burd A; Levine RL; Druker BJ; Bloomfield CD; Byrd JC
    J Hematol Oncol; 2021 Jun; 14(1):96. PubMed ID: 34162404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lower frequency of NPM1 and FLT3-ITD mutations in a South African adult de novo AML cohort.
    Marshall RC; Tlagadi A; Bronze M; Kana V; Naidoo S; Wiggill TM; Carmona SC
    Int J Lab Hematol; 2014 Dec; 36(6):656-64. PubMed ID: 24666762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive molecular understanding of pediatric acute myeloid leukemia.
    Shiba N
    Int J Hematol; 2023 Feb; 117(2):173-181. PubMed ID: 36653696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.